Utility of 99mTc-Sestamibi Heart/Liver Uptake Ratio in Screening Nonalcoholic Fatty Liver Disease During Myocardial Perfusion Imaging,Cancer Biotherapy and Radiopharmaceuticals

当前位置： X-MOL 学术 › Cancer Biother. Radiopharm. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Utility of 99mTc-Sestamibi Heart/Liver Uptake Ratio in Screening Nonalcoholic Fatty Liver Disease During Myocardial Perfusion Imaging
Cancer Biotherapy and Radiopharmaceuticals ( IF 3.4 ) Pub Date : 2022-12-20 , DOI: 10.1089/cbr.2022.0062
Ghazal Norouzi _{1,

2} , Sara Nikdel ₁ , Elahe Pirayesh _{1,

2} , Yazdan Salimi ₃ , Mahasti Amoui _{1,

2} , Hamidreza Haghighatkhah _{2,

4} , Mohammad Ali Ghodsi Rad _{1,

2} , Elmira Javanijouni ₅ , Sepideh Khoshbakht _{1,

2}

Affiliation

Purpose: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic hepatic disease worldwide, with functional impairment of the mitochondria occurring from early stages. Technetium-99m methoxy-isobutyl-isonitrile (99mTc-MIBI) is a lipophilic agent trapped in the mitochondria. This study aims to evaluate the utility of 99mTc-MIBI heart/liver uptake ratio in screening for NAFLD during myocardial perfusion imaging (MPI).

中文翻译：

99mTc-Sestamibi 心/肝摄取率在心肌灌注成像期间筛查非酒精性脂肪肝的效用

目的：非酒精性脂肪性肝病 (NAFLD) 是世界范围内最常见的慢性肝病，其线粒体功能损伤发生在早期阶段。Technetium-99m methoxy-isobutyl-isonitrile (99mTc-MIBI) 是一种截留在线粒体中的亲脂性试剂。本研究旨在评估 99mTc-MIBI 心脏/肝脏摄取比率在心肌灌注成像 (MPI) 期间筛查 NAFLD 的效用。

更新日期：2022-12-20

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>